Concepedia

Publication | Open Access

A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

DOIFull Paper Access

34

Citations

13

References

2013

Year

Lorenza Rimassa, Tiziana Pressiani, C. Boni, Carlo Carnaghi, Elena Rota Caremoli, S. Fagiuoli, Paolo Foa, Stefania Salvagni, Enrico Cortesi, Maria Chiara Tronconi,
The Oncologist

Abstract

Escalated-dose sorafenib in patients with advanced HCC who progressed while on sorafenib, failed to provide any clinical benefit. Second-line treatment still remains an open issue to be explored in appropriate clinical trials.

References

YearCitations

Page 1